8-K: Foghorn Therapeutics Provides 2023 Financial Update and Outlines Strategic Priorities

Foghorn Therapeutics reported its 2023 financial results, highlighted clinical progress, and provided a strategic outlook, including a cash runway into the first half of 2026.

Summary

• Foghorn Therapeutics announced its financial results for the year ended December 31, 2023, reporting collaboration revenues of $34.2 million, compared to $19.2 million in 2022.
• Research and development expenses increased to $109.7 million from $105.6 million in the previous year, while general and administrative expenses rose to $32.4 million from $30.7 million.
• The company's net loss for 2023 was $98.4 million, an improvement from the $108.9 million loss in 2022.
• As of December 31, 2023, Foghorn had $234.1 million in cash, cash equivalents, and marketable securities, which is expected to fund operations into the first half of 2026.
• The company is advancing its pipeline, with dose escalation ongoing in the FHD-286 combination study in AML, and clinical data expected in the second half of 2024.
• Lilly has selected FHD-909, a first-in-class BRM selective inhibitor, for clinical development, with an IND planned for the second quarter of 2024, targeting non-small cell lung cancer.
• Preclinical data for selective CBP and EP300 degraders will be presented at AACR, with IND-enabling studies for the CBP degrader program planned by the end of 2024.
• Foghorn anticipates at least six new INDs targeting significant oncology patient populations over the next four years.

Sentiment

Score: 7

Explanation: The document presents a positive outlook with strong financial backing, clinical progress, and strategic partnerships. However, the company is still in the development stage and faces inherent risks.

Positives

• The company has a strong cash position of $234.1 million, providing a runway into the first half of 2026.
• Collaboration revenues increased significantly year-over-year, driven by the Merck collaboration termination.
• The net loss decreased compared to the previous year, indicating improved financial performance.
• The company is making progress with its clinical programs, including FHD-286 in AML and FHD-909 with Lilly.
• Foghorn's pipeline is expanding, with multiple programs advancing towards IND filings.
• Preclinical data for CBP and EP300 degraders show promising results, with no observed thrombocytopenia at efficacious doses.

Negatives

• Research and development expenses increased to $109.7 million, reflecting continued investment in the platform and early-stage research.
• General and administrative expenses also increased to $32.4 million, due to investments to support the growing business.
• The company reported a net loss of $98.4 million for the year, although this is an improvement from the previous year.

Risks

• The company's clinical trials are subject to inherent risks and uncertainties, which could impact timelines and outcomes.
• The company's ability to obtain regulatory approvals for its product candidates is not guaranteed.
• The company's reliance on CDMOs and CROs for manufacturing and research needs could pose risks.
• The company's business is subject to macroeconomic and geopolitical risks.
• The company may need to raise additional capital in the future.

Future Outlook

Foghorn anticipates at least six new INDs targeting significant oncology patient populations over the next four years and expects to continue advancing its pipeline with multiple programs.

Management Comments

• Adrian Gottschalk, President and Chief Executive Officer of Foghorn, stated that the research and clinical advances made in 2023 set the stage for Foghorn to deliver significant value with the potential for several differentiated, high-impact medicines in 2024 and beyond.
• The company believes FHD-286 has the potential to be a first-in-class broad-based differentiation therapeutic in AML.

Industry Context

Foghorn is operating in the competitive oncology space, focusing on novel targets within the chromatin regulatory system. The company's collaboration with Lilly highlights the industry's interest in this area. The development of selective inhibitors and degraders is a growing trend in cancer therapeutics.

Comparison to Industry Standards

• Foghorn's collaboration with Lilly is similar to other biotech companies partnering with larger pharmaceutical firms to advance drug development.
• The focus on chromatin biology and targeted protein degradation is a relatively new area, with few direct comparables, making Foghorn a pioneer in this space.
• The company's cash runway into the first half of 2026 is a positive sign, as many biotech companies face funding challenges.
• The reported net loss is typical for a clinical-stage biotech company, as significant R&D investments are required before commercialization.
• The company's pipeline of multiple INDs over the next four years is comparable to other companies with similar platforms.

Stakeholder Impact

• Shareholders will be interested in the company's financial performance and clinical progress.
• Employees will be impacted by the company's growth and development.
• Patients may benefit from the company's development of new cancer therapies.
• Partners like Lilly will be impacted by the progress of the collaboration programs.
• Suppliers and creditors will be impacted by the company's financial stability.

Next Steps

• Continue dose escalation in the FHD-286 combination study in AML.
• Present preclinical data for CBP and EP300 degraders at the AACR Annual Meeting.
• File an IND for FHD-909 in the second quarter of 2024.
• Begin IND-enabling studies for the CBP degrader program by the end of 2024.
• Advance other preclinical assets towards IND filings.
• Continue to explore the potential of the Gene Traffic Control Platform.

Key Dates

Keywords

Oncology, Precision Medicine, Chromatin Biology, Gene Traffic Control Platform, FHD-286, FHD-909, BRM Inhibitor, CBP Degrader, EP300 Degrader, AML, NSCLC, IND, Lilly Collaboration